Biotron Limited
BITRF
Other OTC0.00
USD
- -
- -
Biotron Limited
BITRF
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biotron Limited (BITRF) is an Australian biotechnology company focused on developing antiviral therapeutics targeting the viral replication process. The company offers a pipeline of small molecule drugs, including BIT225, an investigational treatment for HIV that inhibits the virus's Vpu protein to enhance immune response; and other candidates targeting dengue fever, hepatitis C, and influenza through its proprietary mechanism targeting viral protein assembly. These products aim to address unmet needs in antiviral therapy by disrupting conserved viral processes rather than specific mutations, providing broad-spectrum potential; services include preclinical and clinical development stages across these programs. Biotron operates primarily in Australia with global development partnerships, founded in 2002 and headquartered in Melbourne. In recent developments, Biotron has advanced its clinical pipeline with ongoing Phase II trials for BIT225 in HIV patients, reporting positive interim data on viral load reduction and immune restoration within the last two years. The company secured additional funding through a capital raise in 2024 to support expanded trials and manufacturing scale-up for dengue and influenza candidates. No major acquisitions or name changes have occurred recently, but Biotron announced a strategic research collaboration with international academic institutions to accelerate preclinical studies for emerging viral threats.